CN103054842A - N-(2-芳基-丙酰基)-磺酰胺在制备治疗脊髓损伤用的药物中的用途 - Google Patents
N-(2-芳基-丙酰基)-磺酰胺在制备治疗脊髓损伤用的药物中的用途 Download PDFInfo
- Publication number
- CN103054842A CN103054842A CN2012104176511A CN201210417651A CN103054842A CN 103054842 A CN103054842 A CN 103054842A CN 2012104176511 A CN2012104176511 A CN 2012104176511A CN 201210417651 A CN201210417651 A CN 201210417651A CN 103054842 A CN103054842 A CN 103054842A
- Authority
- CN
- China
- Prior art keywords
- group
- sci
- general formula
- chemical compound
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000020431 spinal cord injury Diseases 0.000 title claims abstract description 67
- 229940124530 sulfonamide Drugs 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 42
- 230000006378 damage Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 210000004248 oligodendroglia Anatomy 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 6
- -1 carboxyl carbonyl Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005544 phthalimido group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 230000033001 locomotion Effects 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 210000003141 lower extremity Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 208000037816 tissue injury Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 0 CC(C(NS(C)=O)=O)C1=CC*(C)=CC=C1 Chemical compound CC(C(NS(C)=O)=O)C1=CC*(C)=CC=C1 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000083730 Scione Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- NTEURBORARLYJB-UHFFFAOYSA-N n-methylsulfonylpropanamide Chemical compound CCC(=O)NS(C)(=O)=O NTEURBORARLYJB-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04007177A EP1579859B1 (en) | 2004-03-25 | 2004-03-25 | Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
| EP04007177.1 | 2004-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800095602A Division CN1933825A (zh) | 2004-03-25 | 2005-03-17 | N－(2－芳基－丙酰基)－磺酰胺在治疗脊髓损伤上的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103054842A true CN103054842A (zh) | 2013-04-24 |
Family
ID=34854609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104176511A Pending CN103054842A (zh) | 2004-03-25 | 2005-03-17 | N-(2-芳基-丙酰基)-磺酰胺在制备治疗脊髓损伤用的药物中的用途 |
| CNA2005800095602A Pending CN1933825A (zh) | 2004-03-25 | 2005-03-17 | N－(2－芳基－丙酰基)－磺酰胺在治疗脊髓损伤上的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800095602A Pending CN1933825A (zh) | 2004-03-25 | 2005-03-17 | N－(2－芳基－丙酰基)－磺酰胺在治疗脊髓损伤上的用途 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090030083A1 (https=) |
| EP (1) | EP1579859B1 (https=) |
| JP (1) | JP4988550B2 (https=) |
| KR (2) | KR101327150B1 (https=) |
| CN (2) | CN103054842A (https=) |
| AT (1) | ATE347883T1 (https=) |
| AU (1) | AU2005226901B2 (https=) |
| BR (1) | BRPI0509167A (https=) |
| CA (1) | CA2555162C (https=) |
| CY (1) | CY1107562T1 (https=) |
| DE (1) | DE602004003673T2 (https=) |
| DK (1) | DK1579859T3 (https=) |
| ES (1) | ES2279248T3 (https=) |
| IL (1) | IL177169A (https=) |
| MX (1) | MXPA06009085A (https=) |
| NO (1) | NO20064793L (https=) |
| NZ (1) | NZ548917A (https=) |
| PL (1) | PL1579859T3 (https=) |
| PT (1) | PT1579859E (https=) |
| RU (1) | RU2396075C2 (https=) |
| SI (1) | SI1579859T1 (https=) |
| WO (1) | WO2005092315A1 (https=) |
| ZA (1) | ZA200608517B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039876A1 (en) * | 2006-09-26 | 2008-04-03 | Case Western Reserve University | Cytokine signaling |
| EP2308484A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| CN103172547B (zh) * | 2011-12-20 | 2016-10-12 | 天津市国际生物医药联合研究院 | 磺酰胺衍生物的制备及其应用 |
| CN103159674A (zh) * | 2013-04-03 | 2013-06-19 | 苏州安诺生物医药技术有限公司 | 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途 |
| KR20220064039A (ko) | 2020-11-11 | 2022-05-18 | 정성삼 | 척수 손상 예방 또는 치료용 조성물 |
| KR102320780B1 (ko) | 2021-01-29 | 2021-11-02 | 정성삼 | 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| IT1318466B1 (it) * | 2000-04-14 | 2003-08-25 | Dompe Spa | Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria. |
| ITMI20010206A1 (it) * | 2001-02-02 | 2002-08-02 | Dompe Spa | Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz |
-
2004
- 2004-03-25 PT PT04007177T patent/PT1579859E/pt unknown
- 2004-03-25 AT AT04007177T patent/ATE347883T1/de active
- 2004-03-25 ES ES04007177T patent/ES2279248T3/es not_active Expired - Lifetime
- 2004-03-25 SI SI200430194T patent/SI1579859T1/sl unknown
- 2004-03-25 DE DE602004003673T patent/DE602004003673T2/de not_active Expired - Lifetime
- 2004-03-25 EP EP04007177A patent/EP1579859B1/en not_active Expired - Lifetime
- 2004-03-25 PL PL04007177T patent/PL1579859T3/pl unknown
- 2004-03-25 DK DK04007177T patent/DK1579859T3/da active
-
2005
- 2005-03-17 BR BRPI0509167-5A patent/BRPI0509167A/pt active Search and Examination
- 2005-03-17 WO PCT/EP2005/002822 patent/WO2005092315A1/en not_active Ceased
- 2005-03-17 MX MXPA06009085A patent/MXPA06009085A/es active IP Right Grant
- 2005-03-17 CN CN2012104176511A patent/CN103054842A/zh active Pending
- 2005-03-17 KR KR1020127023407A patent/KR101327150B1/ko not_active Expired - Fee Related
- 2005-03-17 RU RU2006137575/15A patent/RU2396075C2/ru not_active IP Right Cessation
- 2005-03-17 AU AU2005226901A patent/AU2005226901B2/en not_active Ceased
- 2005-03-17 KR KR1020067018031A patent/KR101312235B1/ko not_active Expired - Fee Related
- 2005-03-17 CN CNA2005800095602A patent/CN1933825A/zh active Pending
- 2005-03-17 JP JP2007504310A patent/JP4988550B2/ja not_active Expired - Fee Related
- 2005-03-17 NZ NZ548917A patent/NZ548917A/en not_active IP Right Cessation
- 2005-03-17 CA CA2555162A patent/CA2555162C/en not_active Expired - Fee Related
- 2005-03-17 US US10/588,454 patent/US20090030083A1/en not_active Abandoned
-
2006
- 2006-07-31 IL IL177169A patent/IL177169A/en not_active IP Right Cessation
- 2006-10-12 ZA ZA2006/08517A patent/ZA200608517B/en unknown
- 2006-10-23 NO NO20064793A patent/NO20064793L/no not_active Application Discontinuation
-
2007
- 2007-02-22 CY CY20071100248T patent/CY1107562T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005226901B2 (en) | 2011-06-02 |
| US20090030083A1 (en) | 2009-01-29 |
| JP4988550B2 (ja) | 2012-08-01 |
| ES2279248T3 (es) | 2007-08-16 |
| PT1579859E (pt) | 2007-03-30 |
| ATE347883T1 (de) | 2007-01-15 |
| MXPA06009085A (es) | 2007-04-02 |
| JP2007530478A (ja) | 2007-11-01 |
| DE602004003673T2 (de) | 2007-10-04 |
| BRPI0509167A (pt) | 2007-09-11 |
| NO20064793L (no) | 2006-10-23 |
| CA2555162C (en) | 2012-11-27 |
| AU2005226901A1 (en) | 2005-10-06 |
| ZA200608517B (en) | 2008-04-30 |
| KR20120104445A (ko) | 2012-09-20 |
| NZ548917A (en) | 2010-06-25 |
| EP1579859A1 (en) | 2005-09-28 |
| CA2555162A1 (en) | 2005-10-06 |
| PL1579859T3 (pl) | 2007-06-29 |
| CN1933825A (zh) | 2007-03-21 |
| CY1107562T1 (el) | 2013-03-13 |
| KR101312235B1 (ko) | 2013-09-26 |
| SI1579859T1 (sl) | 2007-04-30 |
| IL177169A (en) | 2010-12-30 |
| RU2396075C2 (ru) | 2010-08-10 |
| KR101327150B1 (ko) | 2013-11-06 |
| DK1579859T3 (da) | 2007-04-10 |
| DE602004003673D1 (de) | 2007-01-25 |
| IL177169A0 (en) | 2006-12-10 |
| RU2006137575A (ru) | 2008-04-27 |
| WO2005092315A1 (en) | 2005-10-06 |
| EP1579859B1 (en) | 2006-12-13 |
| KR20070018015A (ko) | 2007-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4599062B2 (ja) | 脈管形成抑制剤としてのピリジルアミド | |
| JP2004508404A (ja) | 鎮痛手法 | |
| JP5086322B2 (ja) | Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物 | |
| JP2002519379A (ja) | 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| JPS59130215A (ja) | 錐体外運動障害の軽減法 | |
| JP2003176240A (ja) | ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法 | |
| CN103054842A (zh) | N-(2-芳基-丙酰基)-磺酰胺在制备治疗脊髓损伤用的药物中的用途 | |
| Pai et al. | Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis | |
| AU2003205836B2 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence | |
| JP2004523559A (ja) | 過敏性腸症候群および機能性胃腸症の治療方法 | |
| AU2003205836A1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence | |
| KR100965205B1 (ko) | 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제 | |
| JP2007055900A (ja) | 炎症性疾患の治療及び予防用医薬組成物 | |
| CN116850180B (zh) | 软木花椒素在制备治疗类风湿关节炎的药物中的应用 | |
| JPH11106337A (ja) | 乾癬の処置剤 | |
| HK1184385A (en) | Use of n-(2-aryl-propionyl)-sulfonamides for the preparation of a medicament for the treatment of spinal cord injury | |
| Skupsky et al. | P137 LOCAL CRAC CHANNEL BLOCKADE TREATS COLITIS IN MICE | |
| HK1101358A (en) | Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury | |
| JP2016166148A (ja) | 虚血性疾患治療薬 | |
| JPWO2008093495A1 (ja) | 多発性硬化症治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1184385 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: DOMPE PHARMACEUTICAL S. P. A. Free format text: FORMER OWNER: DOMPE S.P.A. Effective date: 20150902 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150902 Address after: Milan Italy Applicant after: DOMPE SPA Address before: Italy Aquila Applicant before: Dompe S. P. A. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130424 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1184385 Country of ref document: HK |